Component
New vertebral fractures in the SOTI trial
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In 1,649 postmenopausal women with osteoporosis and a prior vertebral fracture, 2 g/day ranelate reduced new vertebral-fracture risk over three years: relative risk 0.59, 95% CI 0.48–0.73.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Randomized placebo-controlled SOTI trial; both groups received calcium and vitamin D.
- limitations
- Specific drug, population and co-treatment; no equivalent efficacy established for dietary strontium or strontium citrate. Trial mechanisms are not identified by the fracture endpoint.
- nutrient_topic
- Strontium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Strontium
- plain_language
- A clinical trial measured fewer fractures, separately from density scans.
- primary_references
- The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. · 2004 · https://pubmed.ncbi.nlm.nih.gov/14749454/ · DOI 10.1056/NEJMoa022436
Strontium: calcium interactions, cellular mechanisms and mineralization (2026-09-19) · lines 422–428
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Randomized placebo-controlled SOTI trial; both groups received calcium and vitamin D. · source_derived_draft · unverified_draft
## strontium-soti-fractures A clinical trial measured fewer fractures, separately from density scans. In 1,649 postmenopausal women with osteoporosis and a prior vertebral fracture, 2 g/day ranelate reduced new vertebral-fracture risk over three years: relative risk 0.59, 95% CI 0.48–0.73. Model: Randomized placebo-controlled SOTI trial; both groups received calcium and vitamin D. Limitations: Specific drug, population and co-treatment; no equivalent efficacy established for dietary strontium or strontium citrate. Trial mechanisms are not identified by the fracture endpoint. Evidence access: Primary abstract The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. · 2004 · https://pubmed.ncbi.nlm.nih.gov/14749454/ · DOI 10.1056/NEJMoa022436
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.